Elevated systolic blood pressure in male GH transgenic mice is age dependent

Endocrinology

Volumn 155, Issue 3, 2014, Pages 975-986

  Jara, Adam ^a,b   Benner, Chance M ^a   Sim, Don ^a   Liu, Xingbo ^a   List, Edward O ^a,b   Householder, Lara A ^a   Berryman, Darlene E ^a,b   Kopchick, John J ^a,b  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GROWTH HORMONE; INSULIN; MESSENGER RNA;

ACROMEGALY; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELEVATED BLOOD PRESSURE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEART; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HYPERINSULINEMIA; HYPOINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; WILD TYPE;

ACROMEGALY; ANIMALS; BLOOD PRESSURE; BODY COMPOSITION; BODY WEIGHT; CATTLE; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TOLERANCE TEST; GROWTH HORMONE; HOMEOSTASIS; HYPERTENSION; INSULIN; KIDNEY GLOMERULUS; MALE; MICE; MICE, TRANSGENIC; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; SYSTOLE; TIME FACTORS;

EID: 84896805392     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1899     Document Type: Article

References (64)

1. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3:17.
2. Boysan SN, Kantarci F, Celik O, Mihmanli I, Gazioglu N, Kadioglu P. Atherosclerotic risk factors and premature atherosclerosis in acromegaly before and after 48 months of octreotide-LAR treatment. Angiology. 2012;63:522-527.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102-152. (Pubitemid 38269977)
4. Schwarz ER, Jammula P, Gupta R, Rosanio S. A case and review of acromegaly-induced cardiomyopathy and the relationship between growth hormone and heart failure: cause or cure or neither or both? J Cardiovasc Pharmacol Ther. 2006;11:232-244. (Pubitemid 44936237)
5. Colao A. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary. 2012;15:50-58.
6. Chen WY, White ME, Wagner TE, Kopchick JJ. Functional antagonism between endogenous mouse growth hormone (GH) and aGH analog results in dwarf transgenic mice. Endocrinology. 1991;129: 1402-1408.
7. Naar EM, Bartke A, Majumdar SS, Buonomo FC, Yun JS, Wagner TE. Fertility of transgenic female mice expressing bovine growth hormone or human growth hormone variant genes. Biol Reprod. 1991;45:178-187.
8. Palmer AJ, Chung MY, List EO, et al. Age-related changes in body composition of bovine growth hormone transgenic mice. Endocrinology. 2009;150:1353-1360.
9. Berryman DE, List EO, Coschigano KT, Behar K, Kim JK, Kopchick JJ. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res. 2004;14:309-318. (Pubitemid 38878057)
10. Ding J, Berryman DE, Kopchick JJ. Plasma proteomic profiles of bovine growth hormone transgenic mice as they age. Transgenic Res. 2011;20:1305-1320.
11. Dominici FP, Balbis A, Bartke A, Turyn D. Role of hyperinsulinemia on hepatic insulin receptor concentration and autophosphorylation in the presence of high growth hormone levels in transgenic mice overexpressing growth hormone gene. J Endocrinol. 1998;159:15-25. (Pubitemid 28459262)
12. Andersson IJ, Johansson ME, Wickman A, et al. Endothelial dysfunction in growth hormone transgenic mice. Clin Sci (Lond). 2006; 110:217-225. (Pubitemid 43241483)
13. Dilley RJ, Schwartz SM. Vascular remodeling in the growth hormone transgenic mouse. Circ Res. 1989;65:1233-1240. (Pubitemid 19281708)
14. Bollano E, Omerovic E, Bohlooly-y M, et al. Impairment of cardiac function and bioenergetics in adult transgenic mice overexpressing the bovine growth hormone gene. Endocrinology. 2000;141:2229-2235. (Pubitemid 32274377)
15. Bohlooly-Y M, Carlson L, Olsson B, et al. Vascular function and blood pressure in GH transgenic mice. Endocrinology. 2001;142: 3317-3323. (Pubitemid 32681735)
16. Peten EP, Striker LJ, Fogo A, Ichikawa I, Patel A, Striker GE. The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice. Mol Med. 1994;1:104-115.
17. Izzard AS, Emerson M, Prehar S, et al. The cardiovascular phenotype of a mouse model of acromegaly. Growth Horm IGF Res. 2009;19:413-419.
18. Bartke A, Chandrashekar V, Bailey B, Zaczek D, Turyn D. Consequences of growth hormone (GH) overexpression and GH resistance. Neuropeptides. 2002;36:201-208.
19. Colligan PB, Brown-Borg HM, Duan J, Ren BH, Ren J. Cardiac contractile function is enhanced in isolated ventricular myocytes from growth hormone transgenic mice. J Endocrinol. 2002;173: 257-264. (Pubitemid 34552454)
20. Doi SQ, Chilakamarri GC, Mendonca MC, et al. Increased class A scavenger receptor and glomerular lipid precede mesangial matrix expansion in the bGH mouse model. Growth Horm IGF Res. 2010; 20:326-332.
21. Bielohuby M, Roemmler J, Manolopoulou J, et al. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice. Exp Biol Med (Maywood). 2009;234:1002-1009.
22. Giani JF, Miquet JG, Muñoz MC, et al. Upregulation of the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in the heart and the kidney of growth hormone receptor knock-out mice. Growth Horm IGF Res. 2012;22:224-233.
23. Santos RA, Ferreira AJ, Simões E Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93:519-527. (Pubitemid 351595060)
24. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-675.
25. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-622.
26. Ferrannini E, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J Cardiovasc Pharmacol. 1990;15(Suppl 5): S18-S25. (Pubitemid 20159133)
27. Saad MF, Rewers M, Selby J, et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension. 2004;43:1324-1331. (Pubitemid 38691757)
28. Ding J, List EO, Okada S, Kopchick JJ. Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm IGF Res. 2009;19:399-407.
29. Parsons JA, Bartke A, Sorenson RL. Number and size of islets of Langerhans in pregnant, human growth hormone-expressing transgenic, and pituitary dwarf mice: effect of lactogenic hormones. Endocrinology. 1995;136:2013-2021.
30. Boparai RK, Arum O, Khardori R, Bartke A. Glucose homeostasis and insulin sensitivity in growth hormone-transgenic mice: a cross-sectional analysis. Biol Chem. 2010;391:1149-1155.
31. Di Cola G, Cool MH, Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest. 1997;99:2538-2544. (Pubitemid 27227733)
32. Wang J, Zhu X, Chen C, et al. Effect of insulin-like growth factor-1 (IGF-1) on the gluconeogenesis in calf hepatocytes cultured in vitro. Mol Cell Biochem. 2012;362:87-91.
33. Miquet JG, Giani JF, Martinez CS, et al. Prolonged exposure to GH impairs insulin signaling in the heart. J Mol Endocrinol. 2011;47: 167-177.
34. Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology. 1989;124:40-48. (Pubitemid 19033624)
35. Doi T, Striker LJ, Quaife C, et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin like growth factor-1. Am J Pathol. 1988;131:398-403.
36. Doi T, Striker LJ, Gibson CC, Agodoa LY, Brinster RL, Striker GE. Glomerular lesions in mice transgenic for growth hormone and insulin-like growth factor-I. I. Relationship between increased glomerular size and mesangial sclerosis. Am J Pathol. 1990;137:541-552. (Pubitemid 20280984)
37. Machado MO, Hirata RD, Sellitti DF, et al. Growth hormone promotes glomerular lipid accumulation in bGH mice. Kidney Int. 2005;68:2019-2028. (Pubitemid 43117777)
38. Auriemma RS, Galdiero M, De Martino MC, et al. The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. Eur J Endocrinol. 2010;162:1035-1042.
39. Reddy GR, Pushpanathan MJ, Ransom RF, et al. Identification of the glomerular podocyte as a target for growth hormone action. Endocrinology. 2007;148:2045-2055. (Pubitemid 46997041)
40. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
41. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf). 2001;54:137-154. (Pubitemid 32194446)
42. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006;69:318-328. (Pubitemid 43098788)
43. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol. 2011;57:131-140.
44. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808-1817.
45. McKnight J, McCance D, Hadden D, et al. Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly. Clin Endocrinol (Oxf). 1989;31:431-438. (Pubitemid 19238226)
46. Lazúrová I, Pura M, Wagnerová H, et al. Effect of growth hormone replacement therapy on plasma brain natriuretic peptide concentration, cardiac morphology and function in adults with growth hormone deficiency. Exp Clin Endocrinol Diabetes. 2010;118:172-176.
47. Andreassen M, Faber J, Vestergaard H, Kistorp C, Kristensen LO. N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clin Endocrinol (Oxf). 2007;66:619-625. (Pubitemid 46699526)
48. Dirsch V, Wolf E, Wanke R, Schulz R, Hermanns W, Vollmar. A Effect of chronic GH overproduction on cardiac ANP expression and circulating ANP levels. Mol Cell Endocrinol. 1998;144:109.
49. Masternak MM, Bartke A. Growth hormone, inflammation and aging. Pathobiol Aging Age Relat Dis. 2012;2:17293.
50. Coschigano KT, Wetzel AN, Obichere N, et al. Identification of differentially expressed genes in the kidneys of growth hormone transgenic mice. Growth Horm IGF Res. 2010;20:345-355.
51. Wang Z, Masternak MM, Al-Regaiey KA, Bartke A. Adipocytokines and the regulation of lipid metabolism in growth hormone transgenic and calorie-restricted mice. Endocrinology. 2007;148: 2845-2853. (Pubitemid 46984799)
52. Olarescu NC, Ueland T, Godang K, Lindberg-Larsen R, Jorgensen JO, Bollerslev J. Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities. Eur J Endocrinol. 2013;170:39-48.
53. Wan W, Murphy PM. Regulation of atherogenesis by chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz). 2013; 61:1-14.
54. Liao TD, Yang XP, Liu YH, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension. 2008;52:256-263.
55. German AJ, Ryan VH, German AC, Wood IS, Trayhurn P. Obesity, its associated disorders and the role of inflammatory adipokines in companion animals. Vet J. 2010;185:4-9.
56. Wassel CL, Barrett-Connor E, Laughlin GA. Association of circulating C-Reactive protein and interleukin-6 with ongevity into the 80s and 90s: The Rancho Bernardo Study. J Clin Endocrinol Metab. 2010;95:4748-4755.
57. Giovannini S, Onder G, Liperoti R, et al. Interleukin-6, C-reactive protein, and tumor necrosis factor-α as predictors of mortality in frail, community-living elderly individuals. J AmGeriatr Soc. 2011; 59:1679-1685.
58. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA. 1995;92:4862-4866.
59. Banerjee I, Fuseler JW, Intwala AR, Baudino TA. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol. 2009;296:H1694-H704.
60. Funakoshi Y, Ichiki T, Ito K, Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension. 1999;34:118-125. (Pubitemid 29325729)
61. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25:693-721. (Pubitemid 39366048)
62. Söderpalm B, Ericson M, Bohlooly M, Engel JA, Törnell J. Bovine growth hormone transgenic mice display alterations in locomotor activity and brain monoamine neurochemistry. Endocrinology. 1999;140:5619-5625. (Pubitemid 30645349)
63. Bohlooly-Y M, Olsson B, Gritli-Linde A, et al. Enhanced spontaneous locomotor activity in bovine GH transgenic mice involves peripheral mechanisms. Endocrinology. 2001;142:4560-4567. (Pubitemid 32907088)
64. Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf). 2005;63:470-476. (Pubitemid 41442344)